Company news

HLS Therapeutics, Inc. news in 2021

HLS Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

HLS Therapeutics Establishes Automatic Share Purchase Plan

December 20, 2021

HLS Therapeutics to Present at Stifel GMP's Future of Healthcare Conference

December 1, 2021

HLS Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

November 11, 2021

HLS Therapeutics Announces Q3 Fiscal 2021 Financial Results

November 4, 2021

HLS Therapeutics to Host Q3 2021 Financial Results Conference Call

October 21, 2021

HLS Therapeutics to Participate in Two Virtual Non-Deal Roadshows

October 4, 2021

HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada

August 16, 2021

HLS Therapeutics Announces Second Quarter Fiscal 2021 Financial Results

August 5, 2021

HLS Therapeutics to Present at the Canaccord Genuity 41st Annual Growth Conference

August 4, 2021

HLS Therapeutics to Host Q2 2021 Financial Results Conference Call

July 22, 2021

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 16, 2021

June 15, 2021

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on June 10, 2021

June 9, 2021

HLS Therapeutics Announces Participation at Upcoming Investor Conferences

May 26, 2021

HLS Therapeutics Announces First Quarter Fiscal 2021 Financial Results

May 6, 2021

HLS Therapeutics to Host Q1 2021 Financial Results Conference Call

April 22, 2021

HLS Therapeutics Announces Participation in Upcoming Conferences

April 15, 2021

HLS Therapeutics Comments on Rule Enacted by Quebec Health Minister Christian Dubé and the Absence of an Exception for New Refractory Schizophrenic Patients

April 1, 2021

HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

March 29, 2021

HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results

March 18, 2021

HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

March 17, 2021

HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call

March 4, 2021

HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021

February 23, 2021

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021

February 16, 2021

HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®

February 16, 2021

VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events

January 28, 2021

HLS Therapeutics Announces Final Redemption of Preferred Shares

January 4, 2021

Decks in 2021